AVAishwarya Venkataraman

Aishwarya Venkataraman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aishwarya Venkataraman has a total of 157 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Profiling complement proteins in pediatric tuberculosis children with or without serological evidence of prior SARS-CoV-2 exposure

    by Nathella Pavan Kumar, Guruprashath Mohan, Sarath Balaji, Agalya Vanamudhu, Prabhakar R, Balaji Ramraj, Poorna Ganga Devi, Shaik Fayaz Ahamed, Karthik M, Gopika S, et al.

    Introduction: Coinfection with Mycobacterium tuberculosis (TB) and SARS-CoV-2 poses unique challenges in pediatric population due to overlapping immune pathways and potential immune dysregulation. The complement system, a key arm of innate immunity, plays a dual role in pathogen clearance and inflammation. Methods: This study aimed to investigate complement activation in TB in children with or without serological evidence of prior SARS-CoV-2 exposure. Children aged 2–17 years with pulmonary or extrapulmonary TB were recruited from two tertiary hospitals in South India. Participants were grouped based on SARS-CoV-2 IgG serostatus: CoV2⁺ (n = 30) and CoV2⁻ (n = 30). Blood samples were collected at baseline, and at months 3, and 6 for complement profiling. Levels of classical, lectin, and alternative pathway proteins, as well as regulatory factors, were quantified using multiplex bead-based assays. Canonical discriminant analysis (CDA) and Spearman correlation were used to analyse temporal and relational patterns in complement activation. Results: CoV2 + children had significantly elevated levels of classical pathway proteins (C1q, C3, C4, C5a) and regulatory factors (Factor B, H, and I) at baseline, month 3 and month 6 in comparison to CoV2 - children. However C2 and C5 diminished in CoV2 + children in comparison to CoV2-CDA revealed distinct, time-resolved complement activity in CoV2⁻ children, whereas CoV2⁺ profiles showed overlap, suggesting prolonged immune alteration. Correlation analysis identified significant associations between SARS-CoV-2 IgG and complement proteins, with differing patterns in CoV2 + and CoV2 - groups over time. Discussion: SARS-CoV-2 seropositivity may contribute to changes in the complement activation trajectory in TB-diseased children, potentially contributing to persistent inflammation. Complement profiling may inform therapeutic strategies and serve as a biomarker of immune recovery in TB– SARS-CoV-2 co-infection.

  • Navigating the Challenges of Implementing Tuberculosis Research During COVID-19 Pandemic: Insights from the Pediatric Tuberculosis-Moderate Acute Malnutrition Study

    by Aishwarya Venkataraman, Nancy Hilda Joseph, Gopika Sadanandan, S. Balasubramanian

    Clinical research involving children presents significant challenges due to physiological, ethical, regulatory, and practical considerations unique to this vulnerable population. These intrinsic challenges were amplified during the COVID-19 pandemic, which substantially disrupted pediatric research and child health services. The pandemic exposed critical ethical, operational, and communicative tensions, especially with respect to informed consent, caregiver trust, and safe research implementation. Examining these intersecting challenges can improve and strengthen pediatric research to remain ethically robust and child-centred in the event of future public health crises.

  • Open Access

    Inflammatory cytokine responses in pediatric tuberculosis with or without SARS-CoV-2 seropositivity

    by Nathella Pavan Kumar, Sarath Balaji, Poorna Ganga Devi, Balaji Ramraj, Arul Nancy, Nandhini Selvaraj, Shaik Fayaz Ahamed, Karthik M, Suba S, A. Gunasundari, et al.


  • Open Access

    Current challenges and future development of India’s healthcare system’ towards tuberculosis free India – research evidence and programmatic initiatives

    by N. Gopalan, A. Newtonraj, L. K. Elizabeth, S. K. Shanmugam, U. D. Ranganathan, M. Muniyandi, B. Ramraj, B. Devaleenal, A. Venkataraman, K. Nagarajan, et al.

    Tuberculosis (TB), the single most infectious killer deserves special attention in a focussed manner, to reduce morbidity and mortality. We describe the challenges in the four pillars of TB control: detect or diagnosis, treat, prevent, build and elaborate the success stories, listing out newer and advanced tools like artificial intelligence, whole genome sequencing, clustered regularly interspaced short palindromic repeats based technologies, one health approach and cost effectiveness strategies for an all- round reduction in TB control. Special problems posed by paediatric and extra-pulmonary TB are dealt with. Post TB lung sequalae, reverse zoonosis and behavioural modification that can influence catastrophic costs are explored. Use of molecular and genomic methods of TB detection has revolutionized TB care with increased sensitivity of diagnosis, and timely detection of drug resistance, saving many a precious lives. Undoubtedly, the need of the hour would be shortening TB treatment duration and comprehensive preventive strategies that simultaneously decrease both the incidence and prevalence of TB. The various schemes and initiatives undertaken by the Government of India including the Pradhan Mantri TB Mukt Bharat Abhiyaan – “TB free India” stand as a unique solution in the wake of eliminating TB. India has been extending its success stories to other countries as well, by creating platforms for multilateral research and multinational implementation. This manuscript gives a concise and comprehensive outlook of process involved in TB elimination, amalgamating the research evidences with the programmatic initiatives, enlisting the existing challenges, envisaging the current achievements, providing a road map for TB elimination.


  • Open Access

    Evaluation of platelet indices as markers of tuberculosis among children in India

    by Nancy Hilda J, Aishwarya Venkataraman, Kannan Thiruvengadam, Brindha B, Karthick M, Subha S, Sarath Balaji, Elilarasi S, Melanie Smuk, Luke Elizabeth Hanna, et al.

    Children with tuberculosis have increased platelet count and platelet/lymphocyte ratio along with decreased mean platelet volume, suggesting that these indices may be useful as adjunct tools in diagnosis of paediatric tuberculosis https://bit.ly/3Ga4AWT.


  • Open Access

    Immune Profiles in Multisystem Inflammatory Syndrome in Children with Cardiovascular Abnormalities

    by Nathella Pavan Kumar, Aishwarya Venkataraman, Arul Nancy, Nandhini Selvaraj, Kadar Moideen, Shaik Fayaz Ahamed, Rachel Marriam Renji, Kandasamy Sasidaran, Sandip Kumar, Muthiah Periyakuppan, et al.

    Background: Multisystem inflammatory syndrome in children (MIS-C), a sequela of severe acute respiratory syndrome coronavirus-2 infection (SARS-CoV2), has been progressively reported worldwide, with cardiac involvement being a frequent presentation. Although the clinical and immunological characteristics of MIS-C with and without cardiac involvement have been described, the immunological differences between cardiac and non-cardiac MIS-C are not well understood. Methods: The levels of type 1, type 2, type 17, other proinflammatory cytokines and CC chemokines and CXC chemokines were measured using the Magpix multiplex cytokine assay system in MIS-C children with MIS-C cardiac (MIS-C (C) (n = 88)) and MIS-C non-cardiac (MIS-C (NC) (n = 64)) abnormalities. Results: MIS-C children with cardiac manifestations presented with significantly increased levels of cytokines such as IFN-γ, IL-2, TNFα, IL-5, IL-1α, IL-1β, IL-6, IL-10 and IL-12p70 and chemokines such as CCL2, CCL3, CCL11 and CXCL10 in comparison to MIS-C children without cardiac manifestations. Clustering analysis revealed that cytokines and chemokines could clearly distinguish MIS-C children with and without cardiac manifestations. In addition, these responses significantly diminished and normalized 9 months after treatment. Conclusions: This is one of the first studies characterizing and differentiating systemic inflammation in MIS-C with and without cardiac involvement from a low- and middle-income country (LMIC). Our study contributes to the existing body of evidence and advances our knowledge of the immunopathogenesis of MIS-C in children.


  • Kawasaki Disease in the Time of COVID-19 and MIS-C: The International Kawasaki Disease Registry

    by Ashraf S. Harahsheh, Samay Shah, Frederic Dallaire, Cedric Manlhiot, Michael Khoury, Simon Lee, Marianna Fabi, Daniel Mauriello, Elif Seda Selamet Tierney, Arash A. Sabati, et al.


  • Comparison of two mycobacterial strains in performance of the whole blood mycobacterial growth inhibition assay in Indian children

    by Aishwarya Venkataraman, Sivakumar Shanmugam, Sarath Balaji, Karthick Mani, Ashok Kumar Shanmugavel, Kannan Muthuramalingam, Syed Hissar, Kannan Thiruvengadam, Elilarasi Selladurai, Melanie Smuk, et al.


  • Open Access

    Plasma biomarker profiling of PIMS-TS, COVID-19 and SARS-CoV2 seropositive children – a cross-sectional observational study from southern India.

    by Aishwarya Venkataraman, Nathella Pavan Kumar, Luke Elizabeth Hanna, Sulochana Putlibai, M Karthick, Anuradha Rajamanikam, Kalaimaran Sadasivam, Balasubramanian Sundaram, Subash Babu


  • Open Access

    Correlation of SARS-CoV-2 serology and clinical phenotype amongst hospitalised children in a tertiary children’s hospital in India

    by Aishwarya Venkataraman, S Balasubramanian, Sulochana Putilibai, S Lakshan Raj, Sumanth Amperayani, S Senthilnathan, Anand Manoharan, Arokia Sophi, R Amutha, Kalaimaran Sadasivam, et al.

    Introduction Children usually present with minimal or no symptoms of SARS-CoV-2 infection. Antibody responses to SARS-CoV-2 in children from low- and middle-income countries (LMIC) have not been well described. We describe the prevalence of anti-SARS-CoV-2 antibodies and clinical phenotype of seropositive children admitted to a tertiary children’s hospital in South India. Methods To determine the seropositivity and describe the clinical characteristics of SARS-CoV-2 infection amongst hospitalised children, we performed a prospective clinical data collection and blood sampling of children admitted to Kanchi Kamakoti CHILDS Trust Hospital, Chennai, India over 4 months of the COVID-19 pandemic. In seropositive children, we compared antibody titres between children with and without PIMS-TS. Results Of 463 children, 91 (19.6%) were seropositive. The median (range) age of seropositive children was 5 years (1 month - 17 years). Clinical presentation was consistent with Paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 infection (PIMS-TS) in 48% (44/91) of seropositive children. The median (range) antibody titre was 54.8 (11.1–170.9) AU/ml among all seropositive children. The median antibody titre among the children with PIMS-TS (60.3 AU/mL) was significantly (p=0.01) higher when compared to the children without PIM-TS (54.8 AU/mL). Conclusion We describe the antibody responses to SARS-CoV-2 amongst hospitalised children in a LMIC tertiary children’s hospital. Almost half of the seropositive children had PIMS-TS. Antibody levels may be helpful in the diagnosis and disease stratification of PIMS-TS. Lay summary Children usually present with minimal or no symptoms of SARS-CoV-2 infection. However, Paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 infection (PIMS-TS) has emerged as a distinctive paediatric illness related to SARS-CoV-2. Recently, antibody testing for SARS-CoV-2 is being used increasingly as a diagnostic test for PIMS-TS. However, data on the antibody responses to SARS-CoV-2 in children is sparse. We therefore, attempted to identify the seropositivity and describe the clinical spectrum of SARS-CoV-2 infection amongst infants and children getting hospitalised in a children’s hospital in south India. Nearly one-fifth of the hospitalised children tested serology positive over 4 months. Antibody levels in children with PIMS-TS were significantly higher in comparison to the other two groups (acute SARS-CoV-2 infection and children without PIMS-TS). Results from our study suggest that all children are at risk of SARS-CoV-2 infection though they may present with mild illness or no symptoms. We also observed that antibody testing may have a possible role in diagnosis of PIMS-TS.